Lack of Efficacy of High-Dose Intravenous Immunoglobulin Treatment of Severe Thrombocytopenia in Patients with Secondary Dengue Virus Infection by Dimaano Efren M. et al.
Lack of Efficacy of High-Dose Intravenous Immunoglobulin Treatment of Severe
Thrombocytopenia in Patients with Secondary Dengue Virus Infection
Efren M. Dimaano, Mariko Saito, Shoko Honda, Edna A. Miranda, Maria T. G. Alonzo, Myra D. Valerio,
Cynthia A. Mapua, Shingo Inoue, Atsushi Kumaori, Ronald Matias, Filipinas F. Natividad, and Kazunori Oishi*
Department of Internal Medicine and Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan; Department of
Disaster Prevention System, Faculty of Risk and Crisis Management, Chiba Institute of Science, Chiba, Japan; Laboratory for
Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial
Diseases, Osaka University, Osaka, Japan; Department of Blood Borne Diseases, San Lazaro Hospital, Manila, Research and
Biotechnology Division, St. Luke’s Medical Center, Quezon City, The Philippines
Abstract. Because most cases of secondary dengue virus infection are associated with an increased level of platelet-
associated IgG, a high dose of intravenous immunoglobulin (IVIG) may have an effect on the development of severe
thrombocytopenia in this disease. A randomized, controlled study was conducted with two treatment groups consisting
of a treatment (IVIG) group (n  15) and a non-treatment (non-IVIG) group (n  16) to determine whether a high
dose of IVIG is effective in hastening the recovery from thrombocytopenia in patients with secondary dengue virus
infection. No significant difference was found in the baseline demographic data between the two groups. No adverse
effect of IVIG was observed, but no effect in hastening the recovery of platelet counts was found in patients with
secondary dengue infections. The lack of efficacy of IVIG suggests that platelet clearance by macrophages through Fc
 receptors is not a primary mechanism in this disease.
INTRODUCTION
Dengue virus types 1–4 induce a wide spectrum of clinical
manifestations, including hemorrhagic manifestations associ-
ated with thrombocytopenia and increased vascular perme-
ability. Secondary infections, which are commonly observed
in dengue-endemic areas, are more likely to constitute a risk
factor for dengue hemorrhagic fever (DHF).1 Although den-
gue virus–induced bone marrow suppression decreases plate-
let synthesis, an immune mechanism of thrombocytopenia re-
sulting in increased platelet destruction appears to be opera-
tive in patients with DHF.2,3 This disease is now highly
endemic in more than 100 tropical countries, and the number
of cases has increased dramatically during the past three de-
cades.3,4 More than 1,000 deaths occur annually due to DHF,
and no specific treatment is currently available.
The high frequency of elevated platelet-associated IgG
(PAIgG) in idiopathic thrombocytopenic purpura (ITP) sug-
gests that PAIgG is involved in the mechanisms of thrombo-
cytopenia.5,6 Platelets coated with IgG autoantibodies,
which form PAIgG, undergo accelerated clearance through
Fc receptors that are expressed on tissue macrophages. In-
travenous immunoglobulin (IVIG) is currently a widely ac-
cepted treatment option for ITP. Therapeutic activity of IVIG
in the amelioration of ITP appears to involve the mechanism
of competitive inhibition of activating Fc  receptors on ph-
agocytic macrophages in the mononuclear phagocytic system
by IVIG-sensitized erythrocytes.7 Recent studies demon-
strated that the levels of PAIgG levels were inversely corre-
lated with platelet count in patients in the acute phase of
secondary dengue virus infections.8,9 An increased level of
PAIgG was observed in 73.8–80.8% of patients with second-
ary dengue virus infection. These data indicate that the for-
mation of PAIgG in patients with secondary dengue virus
infection may result in thrombocytopenia due either to plate-
let clearance by macrophages or to platelet lysis. This disease
can be classified as a dengue virus–induced ITP. It was hy-
pothesized, therefore, that Fc  receptor blockade by a high
dose of IVIG might inhibit the development of severe throm-
bocytopenia caused by secondary dengue virus infection. A
previous case report had suggested this effect in a patient with
dengue fever (DF).10
MATERIALS AND METHODS
Patients and study design. The present randomized, con-
trolled study was conducted to determine the efficacy of a
high dose of IVIG in hastening the recovery of platelets or
inhibiting the development of severe thrombocytopenia in
patients with secondary dengue virus infection. Thirty-six pa-
tients clinically suspected of being infected with dengue virus
who fulfilled the inclusion criteria were admitted and enrolled
in the study on the first day of admission (day 1) to San
Lazaro Hospital (Manila, The Philippines) between October
and November 2005. Dengue hemorrhagic fever was diag-
nosed according to World Health Organization (WHO) cri-
teria.11 There were two inclusion criteria for these patients: 1)
an acute phase of dengue illness (within 5 days after the onset
of illness) verified by the particle agglutination test for den-
gue IgM,12 and 2) severe thrombocytopenia (platelet count
between 20,000 L and 80,000/L) without prominent mani-
festation of bleeding or shock. The exclusion criterion was a
present history of platelet transfusion either before or after
admission to the hospital. The study was reviewed and ap-
proved by the Bioethics Committees of San Lazaro Hospital
and St. Luke’s Medical Center. Parents or guardians of all
patients provided written informed consent.
Of the patients enrolled, 34 were confirmed to be infected
with the dengue virus infected on the basis of a positive result
by IgM-capture enzyme-linked immunosorbent assay or re-
verse transcription–polymerase chain reaction.13,14 Three pa-
tients were diagnosed as having primary infections, and 31
patients were diagnosed as having secondary infections by a
hemagglutination inhibition test.15 Laboratory tests were con-
ducted at St. Luke’s Medical Center (Quezon City, The Phil-
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ippines). Enrolled patients with secondary infections were
randomly assigned to the IVIG group and non-IVIG treat-
ment groups by means of sealed envelopes.
Treatment with IVIG. Human immunoglobulin (2.5 g/vial,
Gammamune; Bayer Health Care, Brea, CA) at a dose of 0.4
g/kg/day was given intravenously to each patient in the IVIG
group intravenously at a constant rate of 0.1g/kg/hour on day
2, and was continued each day until the fourth day after ad-
mission (day 4) for three days. The dose and frequency of
IVIG in this study was chosen on the basis of previous inves-
tigations of IVIG to treat ITP.16,17 Standard treatment includ-
ing intravenous fluids was given to all patients, regardless of
group assignment, according to WHO guidelines.11
Evaluation. To determine the effects of a high dose of
IVIG, patients in both groups were requested to remain hos-
pitalized until the seventh day after admission (day 7). The
primary measure of efficacy was an increase in platelets.
Platelet counts in patients of both groups were monitored
daily during hospitalization (days 1–7) and on day three after
discharge (day 10) at an outpatient clinic. The target sample
size could not be estimated for this study because no previous
studies had determined the effects of IVIG on the thrombo-
cytopenia during acute dengue virus infection. A interim
target sample size of 30 was chosen to ensure that there would
be at least a 70% chance for detecting a difference of 40%
(100% versus 60%), with a one-sided alpha level of 0.05, in
the frequency of platelet counts higher than 80,000/L on the
fourth day after admission in patients with dengue illness and
a low platelet count between 20,000 and 80,000/L.8,9
Statistical analysis. All the data are expressed as the mean
± SD. Differences in the demographic and clinical data be-
tween the IVIG group and non-IVIG groups were tested us-
ing either a chi-square test or a Fisher’s exact test for nominal
variables. Differences in laboratory data between the IVIG
and non-IVIG groups were analyzed using a Student’s t-test
for continuous variables. A P value less than 0.05 was con-
sidered significant.
RESULTS
Demographic data. Thirty-one patients with secondary in-
fection were randomized to either the IVIG group (n  15)
or the non-IVIG group (n  16) (Table 1). Ten DF cases and
5 DHF cases (1 DHF I and 4 DHF II) were assigned to the
IVIG group, and 9 DF cases and 7 DHF cases (6 DHF II and
1 DHF III) were assigned to the non-IVIG group. The in-
crease in the hematocrit (mean ± SD) was significantly
greater in DHF patients than in DF patients for both treat-
ment groups (30.0 ± 6.3% versus 13.8 ± 5.3% in the IVIG
group and 29.9 ± 12.9% versus 8.9 ± 4.4% in the non-IVIG
group; P < 0.001). No significant differences were found be-
tween the two groups with respect to demographic and labo-
ratory data including peripheral platelet count and levels of
aspartate aminotransferase and alanine aminotransferase at
day 1.
Treatment with IVIG. Because the lowest platelet counts
were found on day 2, the recovery phase, but not the phase of
development for severe thrombocytopenia, was evaluated in
these patients (Figure 1). Although patients who received
IVIG were carefully monitored for adverse events, none were
observed in patients in this group either during or after treat-
ment. Despite treatment with a high dose of IVIG, no signifi-
cant change in the platelet counts between day 2 (day of
initiation of IVIG treatment) and day 7 was observed in ei-
ther treatment group. Likewise, no difference was found in
the duration of severe thrombocytopenia between the IVIG
and non-IVIG groups (Table 1). No significant difference was
found in platelet counts in the DF and DHF subgroups be-
tween the IVIG and the non-IVIG groups during the same
period.
Levels of PAIgG also were examined in patients in both
groups on days 2, 5, and 10. The PAIgG levels (mean ± SD
ng/107 platelets) increased from baseline on day 2 in both the
IVIG and non-IVIG groups (24.5 ± 15 versus 33.8 ± 28.6),
decreased on day 5 (18.5 ± 8.4 versus 13.7 ± 5.2), and returned
to normal levels (11.0 ± 7.8 versus 8.7 ± 3.7) on day 10, which
is consistent with our previous findings.9 No significant dif-
ference was found in levels of PAIgG in patients in the IVIG
group and the non-IVIG group.
DISCUSSION
Although the patients were enrolled in an early phase of
the illness (less than 4 days after onset), the effect of IVIG on
TABLE 1
Comparison of clinical features of patients with secondary dengue








Mean age, years (SD) 16.3 (3.6) 14.3 (3.4) 0.108
Male % 53.3 43.8 0.594
Mean body weight, kg (SD) 37.8 (10.6) 37.3 (8.7) 0.891
Days after onset (SD) 3.9 (0.6) 3.7 (1.1) 0.462
Laboratory data on day 1
Mean platelet count,
×103/L (SD) 54.9 (12.7) 48.0 (13.1) 0.147
Mean AST, U/L (SD) 129.1 (130.5) 124.0 (69.5) 0.893
Mean ALT, U/L (SD) 100.6 (105.2) 59.5 (31.5) 0.146
Days of severe
thrombocytopenia (SD) 3.1 (1.0) 2.5 (0.8) 0.11
* IVIG  intravenous immunoglobulin; AST  aspartate aminotransferase; ALT 
alanine aminotransferase. Period of severe thrombocytopenia indicates the days of platelet
count between 20,000 L and 80,000/L.
FIGURE 1. Comparison of platelet counts in patients with second-
ary dengue virus infections receiving a high dose of intravenous im-
munoglobulin (IVIG) and intravenous fluids (closed circle) and pa-
tients receiving intravenous fluids alone (open circle). The IVIG at a
dose of 0.4 g/kg/day was given to each patient in the IVIG group on
the second, third, and fourth day after hospital admission.
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recovery of platelet count could be evaluated, but the inhibi-
tory effect on the development of thrombocytopenia could
not evaluated. No adverse effect of IVIG was noted, but there
was no shortening of the time for platelet counts to return to
normal levels in patients with secondary dengue infections.
Because a rapid recovery of platelet counts is typically found
in most patients with severe thrombocytopenia, no additional
management of hemostatic abnormalities, including a high
dose of IVIG, is required for such patients.
Our group recently developed an in vitro assay of phago-
cytosis of human platelets using flowcytometry. With this as-
say, it was shown that phagocytosis of platelets from patients
with secondary infections by macrophages is significantly in-
creased compared with that of platelets from healthy control
subjects (Oishi K. and others, unpublished data). These data
suggest that platelet clearance by macrophages plays a role in
thrombocytopenia in this disease. Collectively, the lack of
efficacy of IVIG in treating severe thrombocytopenia in sec-
ondary dengue virus infection shown in this study suggests
that platelet clearance by macrophages through Fc  recep-
tors is not a primary mechanism of thrombocytopenia in sec-
ondary dengue virus infection. Other immune mechanisms in
this disease may involve platelet clearance by macrophages
through complement receptor 3 (CR3) and complement-
mediated platelet lysis because complement activation medi-
ated by circulating viral antigen is involved in the pathogen-
esis of this disease.6,18
Alternatively, de Castro and others recently conducted a
pilot study to determine whether anti-D (Rh0 D) immuno-
globulin treatment, which resulted in a platelet increase of
more than 70% in Rh+ non-splenectomised patients with ITP,
was effective in increasing platelet counts among pediatric
and adult patients with dengue illness.19 Anti-D immunoglob-
ulin also facilitates immune-mediated clearance of antibody-
coated erythrocytes and spares sensitized platelets because of
preferential destruction of erythrocytes by the mononuclear
phagocytic system in ITP.7,20 Although de Castro and others
demonstrated a trend toward higher platelet counts after
treatment with anti-D immunoglobulin among such patients,
there was no significant difference in the kinetics of platelet
counts between pediatric and adult patients with dengue virus
infection who received anti-D immunoglobulin and those who
received placebo.19
In conclusion, the present study demonstrated a lack of
efficacy for a high dose of IVIG in hastening the recovery of
platelet counts in patients with secondary dengue virus infec-
tion. These data suggest that platelet clearance by macro-
phages through Fc  receptors is not a primary mechanism of
thrombocytopenia in secondary dengue virus infection. Fur-
ther studies are required to identify the immune mechanisms
of thrombocytopenia in secondary dengue virus infection.
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